Endpoints News

Argenx's Vyvgart win in myositis		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

Mon T W Th F

17 August, 2026

For 15 years, Rock Health Summit has brought together founders, clinicians, investors, and enterprise leaders at the intersection of healthcare and technology. Come be a part of it—and meet your next customer or collaborator—with 10% off using discount code EPN-RHS-2026.

sponsored by Medable

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

ENDPOINTS PHARMA

Cytokinetics brings patent suit against Bristol Myers, escalating rivalry

ICER says AstraZeneca’s new blood pressure med isn’t cost-effective

Peer Review

Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board

in case you missed it

Redx tries again at reverse merger, with Skye this time, as alternative route gains steam

Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data

Abcuro gets $66M for Phase 3 in muscle-weakening condition

News Briefing

MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta

FDA approves Bristol Myers' multiple myeloma successor

‘Too big to ban’ WuXi AppTec gains 100% on GLP-1 chokehold

It's been a mixed year for AstraZeneca so far, and today is no exception with the drugmaker reporting one loss and two wins. It said it is ending work on a late-stage trial of a PD-1/CTLA-4 bispecific antibody after an independent committee found that the trial is unlikely to succeed. Read more from Elizabeth Cairns here.

Reynald Castaneda

Deputy Editor, Endpoints News